NR1H4 and metabolic dysfunction-associated steatotic liver disease: However, there are unable to completely interrupt the progression of NAFLD.[12] The Farnesoid X Receptor agonist Obeticholic Acid (OCA) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of NASH.[13] Additionally, microbial therapy, including synbiotics, probiotics, and prebiotics, shows great potential for improving ALT and AST levels in adult patients with NAFLD.[14,15] Surgical treatment has problems associated with postoperative infection, donor inadequacy, and postoperative recurrence.